SEC Contract Filing

Filing Date: 2017-03-13

Document Content:
<DOCUMENT>
<TYPE>EX-10.40
<SEQUENCE>3
<FILENAME>exh1040-opbgxcollaboration.htm
<DESCRIPTION>EXHIBIT 10.40
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
 <!-- Document created using Wdesk 1 -->
 <!-- Copyright 2017 Workiva -->
 <title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sAF6604C375A75C53C098A4388ADDE1C0"></a></div><div><div style="line-height:120%;text-align:right;padding-left:144px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 10.40</font></div><div style="line-height:120%;text-align:right;padding-left:144px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:right;padding-left:144px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">***Text Omitted and Filed Separately </font></div><div style="line-height:120%;text-align:right;padding-left:144px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">with the Securities and Exchange Commission. </font></div><div style="line-height:120%;text-align:right;padding-left:144px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Confidential Treatment Requested </font></div><div style="line-height:120%;text-align:right;padding-left:144px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Under 17 C.F.R. Sections 200.80(b)(4) </font></div><div style="line-height:120%;padding-bottom:8px;text-align:right;padding-left:144px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">and 240.24b-2 </font></div></div><div><br></div><div style="line-height:130%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;font-weight:bold;">RESEARCH COLLABORATION AGREEMENT</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;">THIS AGREEMENT, made effective the </font><font style="font-family:Calibri,sans-serif;font-size:12pt;text-decoration:underline;">28</font><font style="font-family:Calibri,sans-serif;font-size:12pt;text-decoration:underline;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></font><font style="font-family:Calibri,sans-serif;font-size:12pt;">&#32;day of October, 2016 (hereinafter the "Effective Date"), is entered into by and between Ospedale Pediatrico Bambino Ges&#250;, having its address at Rome, Piazza S. Onofrio n. 4 - 00165, extra-territorial area in accordance with the Lateran Treaty, in the person of the President of the Board of Directors and Legal Representative, Ms Mariella Enoc (&#8220;OPBG&#8221;) and Bellicum Pharmaceuticals, Inc., a Delaware corporation, with principal offices located at 2130 W. Holcombe Blvd. Suite 800, Houston, TX 77030 (hereinafter "Bellicum"), each individually a &#8220;Party&#8221; and collectively the &#8220;Parties&#8221;, governing research to be conducted at OPBG and at Bellicum.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;">The Parties agree as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;">WHEREAS Bellicum is engaged in the development of cell and gene therapies;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;">WHEREAS, OPBG is an institution dedicated to research and health care in pediatrics, having intellectual property, know-how and experience regarding cell and gene therapy, and specific know-how regarding same;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;">WHEREAS Bellicum and OPBG are collaborating on Bellicum&#8217;s BPX-501 clinical trial and Bellicum and OPBG desire to expand this collaboration to develop collaborative research projects and additional clinical trials (detailed in exhibit A); and,</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;">WHEREAS Bellicum is willing to fund such collaborative research activities.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;">NOW, THEREFORE, in consideration of the premises and the mutual covenants and conditions hereinafter recited, the parties do hereby agree as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:Calibri,sans-serif;font-size:12pt;font-weigh